RxDoctor Payments Data

Steven Clark

Physician Assistant · Wilton, NYNPI 1861498859

Payments from drug & device makers

$1,013in general payments, 2019–2025

Across 47 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$237
  • Tarsus Pharmaceuticals, Inc.$174
  • Bausch & Lomb Americas Inc.$169
  • Oyster Point Pharma, Inc.$96
  • Novartis$73
  • Biotissue Holdings Inc.$67
  • plus $197 from 7 others

What the payments were for

  • Food & beverage$99398%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,013 in reported general payments places this provider in the 75th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$84,542
Medicare patients
607
Services billed
1,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast65$105,144
RestasisCyclosporine68$103,760
XdemvyLotilaner37$69,248
MieboPerfluorohexyloctane/Pf34$25,257
Cyclosporine36$24,426
TyrvayaVarenicline Tartrate23$17,520
Restasis MultidoseCyclosporine12$10,067
Travoprost17$5,293
SimbrinzaBrinzolamide/Brimonidine Tart19$4,798
Tobramycin-DexamethasoneTobramycin/Dexamethasone77$3,899
CombiganBrimonidine Tartrate/Timolol13$3,119
Bromfenac Sodium15$3,108
Prednisolone Acetate80$2,956
ValacyclovirValacyclovir Hcl51$2,415
Latanoprost86$1,816

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$169$130,40099 claims
AbbVieRestasis, Restasis Multidose, Combigan$237$116,94693 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$174$69,24837 claims
Oyster Point Pharma, Inc.Tyrvaya$96$17,52023 claims
AlconSimbrinza$56$4,79819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Wilton

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →